Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Interventional × Rare Tumor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6065 Neoplasms 3795 Prostatic Neoplasms 2953 Colorectal Neoplasms 2454 Carcinoma, Non-Small-Cell Lung 2352 Lung Neoplasms 2112 Leukemia, Myeloid, Acute 1649 Pancreatic Neoplasms 1591 Multiple Myeloma 1531 Carcinoma, Hepatocellular 1434 Neoplasm Metastasis 1325 Stomach Neoplasms 1261 Lymphoma 1220 Head and Neck Neoplasms 1198 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1188 Brain Neoplasms 1171 Ovarian Neoplasms 1145 Melanoma 1122 Leukemia 1098 Rectal Neoplasms 1061 Recurrence 1043 Colonic Neoplasms 995 Glioblastoma 974 Uterine Cervical Neoplasms 898 Lymphoma, Non-Hodgkin 886 Esophageal Neoplasms 813 Leukemia, Lymphocytic, Chronic, B-Cell 811 Lymphoma, Follicular 771 Lymphoma, Large B-Cell, Diffuse 767 Myelodysplastic Syndromes 764

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡